FRM
MRSN

Fox Run Management’s Mersana Therapeutics MRSN Stock Holding History

Fox Run Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-490
Closed -$54.9K – 958
2024
Q1 		$54.9K Buy
+490
New +$48.7K 0.01% 713
2023
Q4 		– Sell
-873
Closed -$27.7K – 907
2023
Q3 		$27.7K Buy
+873
New +$41.5K 0.01% 663
2023
Q1 		– Sell
-986
Closed -$144K – 835
2022
Q4 		$144K Buy
986
+503
+104% +$85K 0.06% 530
2022
Q3 		$82K Buy
+483
New +$78.5K 0.03% 562
2021
Q4 		– Sell
-471
Closed -$111K – 621
2021
Q3 		$111K Buy
+471
New +$138K 0.07% 423

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fox Run Management's MRSN Position: Q2 2024 in Review

Fox Run Management sold out of Mersana Therapeutics (MRSN) in Q2 2024, closing a stake of 490 shares — an estimated $54.9K sold.

Fox Run Management first reported a position in MRSN in Q3 2021 and held it in 5 quarters. The position peaked at $144K in Q4 2022. 120 funds tracked by Wall St. Rank hold MRSN as of Q2 2024.

  • Fox Run Management reported no remaining Mersana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Fox Run Management sold 490 Mersana Therapeutics shares in Q2 2024, an estimated $54.9K.
  • Fox Run Management first reported a position in Mersana Therapeutics in Q3 2021 and held it in 5 quarters.
  • Fox Run Management's Mersana Therapeutics position peaked at $144K in Q4 2022.
  • 120 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2024.

Based on Fox Run Management's 13F filing for Q2 2024, filed 13 Aug 2024.